OVERALL SURVIVAL (OS) AND PROGRESSION FREE SURVIVAL (PFS) RESULTS FOR A RANDOMIZED PHASE 2 TRIAL OF IPILIMUMAB (IPI) AND PACLITAXEL/CARBOPLATIN (P/C) IN FIRST-LINE STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Lynch, T. J., Jr. [1 ]
Neal, J. [2 ]
Bondarenko, I. [3 ]
Luft, A. [4 ]
Serwatowski, P. [5 ]
Barlesi, F. [9 ]
Chacko, R. [10 ]
Sebastian, M. [6 ]
Cuillerot, J. [7 ]
Reck, M. [8 ]
机构：
[1] Yale Univ, Ctr Canc, New Haven, CT USA
[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
[3] Dnipropetrovsk Municipal Clin Hosp 4, Dept Oncol Radiodiagnosis & Radioth, Dnepropetrovsk, Ukraine
[4] Leningrad Reg Clin Hosp, State Inst, St Petersburg, Russia
[5] Oddzial Chemioterapii, Szczecin, Poland
[6] Johannes Gutenberg Univ Mainz, Mainz, Germany
[7] Bristol Myers Squibb Co, Global Clin Res, Wallingford, CT 06492 USA
[8] Hosp Grosshansdorf, Grosshansdorf, Germany
[9] Univ Mediterranee Assistance Publ Hapitaux Marsei, Marseille, France
[10] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：126 / 126
页数：1
相关论文
共 50 条
  • [1] Overall Survival and Progression Free Survival Results for a Randomized Phase 2 Trial of Ipilimumab (IPI) and Paclitaxel/Carboplatin (P/C) in First-Line Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
    Lynch, T. J.
    Neal, J.
    Bondarenko, I.
    Luft, A.
    Serwatowski, P.
    Barlesi, F.
    Chacko, R.
    Sebastian, M.
    Cuillerot, J.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S515 - S515
  • [2] Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).
    Lynch, T. J.
    Bondarenko, I. N.
    Luft, A.
    Serwatowski, P.
    Barlesi, F.
    Chacko, R. T.
    Sebastian, M.
    Siegel, J.
    Cuillerot, J.
    Reck, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Time trends in overall survival (OS) and progression-free survival (PFS) in the first-line treatment of advanced non-small-cell lung cancer (NSCLC).
    Rutkowski, Jacek
    Saad, Everardo D.
    Buyse, Marc E.
    Jassem, Jacek
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Results of a phase I/II trial of carboplatin/gemcitabine plus celecoxib for first-line treatment of stage IIIB/IV non-small cell lung cancer (NSCLC).
    Burton, JD
    El-Sayah, D
    Cherry, M
    Bhargava, M
    Terjanian, T
    Odaimi, M
    Vesoniaraki, M
    Lowry, J
    Forte, F
    Friscia, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 682S - 682S
  • [5] Progression-free survival (PFS) and overall survival (OS) in phase HI trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC).
    Hotta, K.
    Kiura, K.
    Takigawa, N.
    Tabata, M.
    Fujiwara, Y.
    Tanimoto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] A RANDOMIZED, PHASE 2 STUDY OF PACLITAXEL (P) AND CARBOPLATIN (C) ± CONATUMUMAB (CON) FOR FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC)
    Paz-Ares, L.
    Balint, B.
    de Boer, R.
    van Meerbeeck, J. P.
    Wierzbicki, R.
    Desouza, P. L.
    Galimi, F.
    Haddad, V.
    Hei, Y.
    Ramlau, R.
    ANNALS OF ONCOLOGY, 2010, 21 : 137 - 137
  • [7] Randomized phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small cell lung cancer (NSCLC)
    Saleh, M. N.
    Socinski, M. A.
    Trent, D.
    Dobbs, T.
    Zehngebot, L. M.
    Levine, M. A.
    Stella, P. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Randomized phase II study of vandetanib (V), docetaxel (D), and carboplatin (C) followed by maintenance V or placebo (P) in patients with stage IIIb, IV, or recurrent non-small cell lung cancer (NSCLC): PrECOG PrE0501-Update on maintenance treatment, progression-free survival (PFS), and overall survival (OS).
    Aisner, J.
    Manola, J.
    Dakhil, S. R.
    Stella, P. J.
    Schiller, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Weekly Regimen of Paclitaxel and Carboplatin as First-Line Chemotherapy in Elderly Patients with Stage IIIB-IV Non Small Cell Lung Cancer (NSCLC): Results of a Phase II Study
    Rozzi, A.
    Nardoni, C.
    Corona, M.
    Restuccia, M. R.
    Falbo, T.
    Lanzetta, G.
    JOURNAL OF CHEMOTHERAPY, 2010, 22 (06) : 419 - 423
  • [10] Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
    Lynch, Thomas J.
    Bondarenko, Igor
    Luft, Alexander
    Serwatowski, Piotr
    Barlesi, Fabrice
    Chacko, Raju
    Sebastian, Martin
    Neal, Joel
    Lu, Haolan
    Cuillerot, Jean-Marie
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) : 2046 - 2054
12345